A Phase I/II Study of Venetoclax in Combination With ASTX727 (Cedazuridine/Decitabine) in Treatment-Naïve High-Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1/2
- Enrollment
- 52 patients (estimated)
- Sponsors
- MD Anderson Cancer Center, MD Anderson Cancer Center
- Collaborators
- Genentech, Genentech, MD Anderson Cancer Center
- Tags
- BCL-2 Inhibitor, Chemotherapy, Hypomethylating Agents (HMA)
- Trial Type
- Treatment
- Last Update
- 4 weeks ago
- SparkCures ID
- 1494
- NCT Identifier
- NCT04655755
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.